Clinical correlates of tardive dyskinesia in schizophrenia

Baseline data from the CATIE schizophrenia trial

Del D. Miller, Joseph Patrick McEvoy, Sonia M. Davis, Stanley N. Caroff, Bruce L. Saltz, Miranda H. Chakos, Marvin S. Swartz, Richard S.E. Keefe, Robert A. Rosenheck, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Objective: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Methods: Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. Results: 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Conclusion: Our results confirm the established relationships between the presence of TD and age, duration of treatment with antipsychotics, treatment with a conventional antipsychotic, treatment with anticholinergics, the presence of EPS and akathisia, and substance abuse. Subjects with TD had higher ratings of psychopathology as measured by the PANSS. We found no support for DM or hypertension increasing the risk of TD, or for TD being associated with cognitive impairment.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalSchizophrenia Research
Volume80
Issue number1
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Schizophrenia
Antipsychotic Agents
Psychomotor Agitation
Cholinergic Antagonists
Tardive Dyskinesia
Psychopathology
Substance-Related Disorders
Diabetes Mellitus
Hypertension
Therapeutics
History
Regression Analysis
Clinical Trials

Keywords

  • Antipsychotic adverse effects
  • Clinical features
  • Schizophrenia
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Clinical correlates of tardive dyskinesia in schizophrenia : Baseline data from the CATIE schizophrenia trial. / Miller, Del D.; McEvoy, Joseph Patrick; Davis, Sonia M.; Caroff, Stanley N.; Saltz, Bruce L.; Chakos, Miranda H.; Swartz, Marvin S.; Keefe, Richard S.E.; Rosenheck, Robert A.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Schizophrenia Research, Vol. 80, No. 1, 01.12.2005, p. 33-43.

Research output: Contribution to journalArticle

Miller, DD, McEvoy, JP, Davis, SM, Caroff, SN, Saltz, BL, Chakos, MH, Swartz, MS, Keefe, RSE, Rosenheck, RA, Stroup, TS & Lieberman, JA 2005, 'Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial', Schizophrenia Research, vol. 80, no. 1, pp. 33-43. https://doi.org/10.1016/j.schres.2005.07.034
Miller, Del D. ; McEvoy, Joseph Patrick ; Davis, Sonia M. ; Caroff, Stanley N. ; Saltz, Bruce L. ; Chakos, Miranda H. ; Swartz, Marvin S. ; Keefe, Richard S.E. ; Rosenheck, Robert A. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Clinical correlates of tardive dyskinesia in schizophrenia : Baseline data from the CATIE schizophrenia trial. In: Schizophrenia Research. 2005 ; Vol. 80, No. 1. pp. 33-43.
@article{3a52458c1b8b41ebba834ea749f79917,
title = "Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial",
abstract = "Objective: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Methods: Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. Results: 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Conclusion: Our results confirm the established relationships between the presence of TD and age, duration of treatment with antipsychotics, treatment with a conventional antipsychotic, treatment with anticholinergics, the presence of EPS and akathisia, and substance abuse. Subjects with TD had higher ratings of psychopathology as measured by the PANSS. We found no support for DM or hypertension increasing the risk of TD, or for TD being associated with cognitive impairment.",
keywords = "Antipsychotic adverse effects, Clinical features, Schizophrenia, Tardive dyskinesia",
author = "Miller, {Del D.} and McEvoy, {Joseph Patrick} and Davis, {Sonia M.} and Caroff, {Stanley N.} and Saltz, {Bruce L.} and Chakos, {Miranda H.} and Swartz, {Marvin S.} and Keefe, {Richard S.E.} and Rosenheck, {Robert A.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.schres.2005.07.034",
language = "English (US)",
volume = "80",
pages = "33--43",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Clinical correlates of tardive dyskinesia in schizophrenia

T2 - Baseline data from the CATIE schizophrenia trial

AU - Miller, Del D.

AU - McEvoy, Joseph Patrick

AU - Davis, Sonia M.

AU - Caroff, Stanley N.

AU - Saltz, Bruce L.

AU - Chakos, Miranda H.

AU - Swartz, Marvin S.

AU - Keefe, Richard S.E.

AU - Rosenheck, Robert A.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Objective: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Methods: Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. Results: 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Conclusion: Our results confirm the established relationships between the presence of TD and age, duration of treatment with antipsychotics, treatment with a conventional antipsychotic, treatment with anticholinergics, the presence of EPS and akathisia, and substance abuse. Subjects with TD had higher ratings of psychopathology as measured by the PANSS. We found no support for DM or hypertension increasing the risk of TD, or for TD being associated with cognitive impairment.

AB - Objective: To examine the clinical characteristics of individuals with schizophrenia that develop tardive dyskinesia (TD) associated with antipsychotic treatment. Methods: Baseline data on 1460 patients with schizophrenia were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness schizophrenia study. Subjects who met Schooler-Kane criteria for probable TD were compared to those without TD. Multiple regression analyses were used to examine the relationship between TD and clinical variables. Results: 212 subjects met the Schooler-Kane criteria for probable TD and 1098 had no history or current evidence of TD. Subjects with TD were older, had a longer duration of receiving antipsychotic medication, and were more likely to have been receiving a conventional antipsychotic and an anticholinergic agent. After controlling for important baseline covariates, diabetes mellitus (DM) and hypertension did not predict TD, whereas substance abuse significantly predicted TD. Differences in cognitive functioning were not significantly different after controlling for baseline covariates. The TD subjects also had higher ratings of psychopathology, EPSE, and akathisia. Conclusion: Our results confirm the established relationships between the presence of TD and age, duration of treatment with antipsychotics, treatment with a conventional antipsychotic, treatment with anticholinergics, the presence of EPS and akathisia, and substance abuse. Subjects with TD had higher ratings of psychopathology as measured by the PANSS. We found no support for DM or hypertension increasing the risk of TD, or for TD being associated with cognitive impairment.

KW - Antipsychotic adverse effects

KW - Clinical features

KW - Schizophrenia

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=27744435853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744435853&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2005.07.034

DO - 10.1016/j.schres.2005.07.034

M3 - Article

VL - 80

SP - 33

EP - 43

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -